
Pfizer (PFE) Stock
Pfizer Chart
Company Profile
Price: $25.53
Market Cap: $144.68B
Exchange: NYSE
CEO: Dr. Albert Bourla D.V.M., Ph.D.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 88.00K
Headquarters: New York, NY
Website: Pfizer
Business Summary
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer News
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), demonstrating a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo plus XTANDI in patients with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. The TALAPRO-2 results will be presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium in San Francisco and featured in the ASCO GU official Press Program. The TALAPRO-2 study evaluated two sets of patients, unselected (cohort 1) and selected for HRR gene-mutations (cohort 2). Overall survival was a prespecified, alpha-protected key secondary endpoint. After more than four years of median follow-up (52.5 months), the median OS in cohort 1 was 45.8 months with TALZENNA in combination with XTANDI, and 37.0 months with XTANDI and placebo (Hazard Ratio [HR] of 0.80; 95% Confidence Interval [CI], 0.66-0.96; p=0.015), representing a 20% reduction in the risk of death. This represents a nearly 9-month gain in median OS versus standard of care XTANDI. Data from cohort 1 will be presented today at ASCO GU in an oral presentation (Abstract LBA18) by Dr. Neeraj Agarwal, global lead investigator for TALAPRO-2. aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); In Cohort 2, a statistically significant and clinically meaningful improvement in OS was observed in patients with HRR-mutated mCRPC. At a median follow-up of 44.2 months, the median OS was 45.1 months with TALZENNA in combination with XTANDI, and 31.1 months with XTANDI and placebo (HR of 0.62; 95% CI, 0.48-0.81; p=0.0005), a 38% reduction in the risk of death. This result represents a 14-month gain in median OS versus standard of care XTANDI in a patient population with a historically poor prognosis. The OS improvement in the HRR-mutated population was observed in patients in both BRCA and non-BRCA gene alterations. Dr. Karim Fizazi, Institut Gustave Roussy, University of Paris-Saclay will share data from Cohort 2 at ASCO GU today (Abstract LBA141). “Since its approval, TALZENNA in combination with XTANDI has redefined the standard of care for those living with homologous recombination repair gene-mutated mCRPC. These latest data from TALAPRO-2 are extremely compelling, demonstrating that the combination significantly extended overall survival, in patients selected and unselected for HRR gene alterations, potentially shifting the treatment paradigm for all men living with mCRPC,” said Roger Dansey, M.D., Chief Oncology Officer, Pfizer. “Although definitive conclusions cannot be drawn across studies, these results appear to represent the longest median overall survival reported in a randomized, controlled Phase 3 trial in mCRPC. We look forward to continuing to work with global authorities to potentially update the TALZENNA label with these results.” “TALAPRO-2 is the first study demonstrating a significant and clinically meaningful survival benefit using a combination of PARP and androgen receptor inhibitors in mCRPC,” said Neeraj Agarwal, M.D., FASCO, Professor and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, University of Utah, and global lead investigator for TALAPRO-2. “Survival rates in metastatic castration-resistant prostate cancer are poor due to the advanced and aggressive stage of the disease. Today’s results demonstrate the potential for TALZENNA in combination with XTANDI to be a practice-changing treatment to help improve patient survival in mCRPC.” At the time of the final analysis, updated radiographic progression free survival (rPFS) and other secondary efficacy endpoints demonstrated maintained clinical benefit in both cohorts and were consistent with the primary analyses previously reported and published in The Lancet and Nature Medicine. In addition to the FDA, these data have been shared with the European Medicines Agency (EMA) and other global health authorities to support potential updates of the approved labels for TALZENNA. The safety profile of TALZENNA plus XTANDI was generally consistent with the known safety profile of each medicine. The most common all-cause adverse events in the TALZENNA group (≥30% of patients) were anemia, neutropenia, and fatigue, and the most common (≥10% of patients) grade 3–4 adverse events were anemia (49%) and neutropenia (19.3%). Adverse events were generally manageable with dose modification and supportive care. About Metastatic Castration-Resistant Prostate Cancer Prostate cancer is the second most common cancer in men and the fifth most common cause of cancer death among men worldwide, with an estimated 1.4 million new cases diagnosed in 2022.1 In the U.S., it is the most common cancer in men.2 mCRPC is a cancer that has spread beyond the prostate gland and has progressed despite medical or surgical treatment to lower testosterone. Approximately 10–20% of prostate cancer patients develop mCRPC within 5−7 years of diagnosis.3 Between 1.2–2.1% of all prostate cancer cases globally are mCRPC.4 About TALAPRO-2 The Phase 3 TALAPRO-2 trial is a multicenter, randomized, double-blind, placebo-controlled study that enrolled 1,035 unique patients with mCRPC who had not received new life-prolonging systemic treatments after documentation of mCRPC at sites in the U.S., Canada, Europe, South America, and the Asia-Pacific region. The study included two patient cohorts: unselected (n=805, of whom 169 had HRR mutations and 636 did not) and those with HRR gene mutations (n=399, including 169 patients from Cohort 1 and 230 subsequently enrolled to comprise Cohort 2). Patients with castrate testosterone levels were randomized to receive TALZENNA 0.5 mg/day plus XTANDI 160mg/day, or placebo plus XTANDI 160mg/day. The primary endpoint of the trial was rPFS, defined as the time from the date of randomization to first objective evidence of radiographic progression by blinded independent central review (BICR), or death, whichever occurred first, in both Cohort 1 (unselected) and Cohort 2 (those with HRRm). Secondary endpoints included OS, objective response rate (ORR), duration of response (DoR), prostate-specific antigen (PSA) response, time to cytotoxic chemotherapy and PFS2. For more information on the TALAPRO-2 trial (NCT03395197), go to www.clinicaltrials.gov. About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks PARP enzyme activity and traps PARP at the site of DNA damage, leading to decreased cancer cell growth and cancer cell death. TALZENNA was initially approved in the U.S., EU, and multiple other regions as a single agent for the treatment of adult patients with deleterious or suspected deleterious gBRCAm HER2-negative locally advanced or metastatic breast cancer. TALZENNA in combination with XTANDI was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with HRR gene-mutated mCRPC in June 2023. The combination was also approved by the European Commission in January 2024 for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated. TALZENNA is the first and only PARP inhibitor licensed in the European Union for use with XTANDI for patients with mCRPC, with or without gene mutations. TALZENNA in combination with XTANDI is now approved in more than 40 countries globally for patients with mCRPC, indications vary by country. TALZENNA® (talazoparib) Indication in the U.S. TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for: HRR gene-mutated mCRPC: In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). Breast Cancer: As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. TALZENNA® (talazoparib) Important Safety Information WARNINGS and PRECAUTIONS Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), including cases with a fatal outcome, has been reported in patients who received TALZENNA. Overall, MDS/AML has been reported in 0.4% (3 out of 788) of solid tumor patients treated with TALZENNA as a single agent in clinical studies. In TALAPRO-2, MDS/AML occurred in 2 out of 511 (0.4%) patients treated with TALZENNA and enzalutamide and in 0 out of 517 (0%) patients treated with placebo and enzalutamide. The durations of TALZENNA treatment in these five patients prior to developing MDS/AML were 0.3, 1, 2, 3, and 5 years, respectively. Most of these patients had received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy. Do not start TALZENNA until patients have adequately recovered from hematological toxicity caused by previous chemotherapy. Monitor blood counts monthly during treatment with TALZENNA. For prolonged hematological toxicities, interrupt TALZENNA and monitor blood counts weekly until recovery. If counts do not recover within 4 weeks, refer the patient to a hematologist for further investigations including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue TALZENNA. Myelosuppression consisting of anemia, neutropenia, and/or thrombocytopenia have been reported in patients treated with TALZENNA. In TALAPRO-2, Grade ≥3 anemia, neutropenia, and thrombocytopenia were reported, respectively, in 45%, 18%, and 8% of patients receiving TALZENNA and enzalutamide. Overall, 39% of patients (199/511) required a red blood cell transfusion, including 22% (111/511) who required multiple transfusions. Discontinuation due to anemia, neutropenia, and thrombocytopenia occurred, respectively, in 7%, 3%, and 0.4% of patients. Withhold TALZENNA until patients have adequately recovered from hematological toxicity caused by previous therapy. Monitor blood counts monthly during treatment with TALZENNA. If hematological toxicities do not resolve within 28 days, discontinue TALZENNA and refer the patient to a hematologist for further investigations including bone marrow analysis and blood sample for cytogenetics. Embryo-Fetal Toxicity TALZENNA can cause fetal harm when administered to pregnant women. Advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment with TALZENNA and for 4 months after receiving the last dose. ADVERSE REACTIONS In TALAPRO-2, serious adverse reactions reported in >2% of patients included anemia (9%) and fracture (3%). Fatal adverse reactions occurred in 1.5% of patients, including pneumonia, COVID infection, and sepsis (1 patient each). The most common adverse reactions (≥ 10%, all Grades), including laboratory abnormalities, for patients in the TALAPRO-2 study who received TALZENNA in combination with enzalutamide vs patients receiving placebo with enzalutamide were hemoglobin decreased (79% vs 34%), neutrophils decreased (60% vs 18%), lymphocytes decreased (58% vs 36%), fatigue (49% vs 40%), platelets decreased (45% vs 8%), calcium decreased (25% vs 11%), nausea (21% vs 17%), decreased appetite (20% vs 14%), sodium decreased (22% vs 20%), phosphate decreased (17% vs 13%), fractures (14% vs 10%), magnesium decreased (14% vs 12%), dizziness (13% vs 9%), bilirubin increased (11% vs 7%), potassium decreased (11% vs 7%), and dysgeusia (10% vs 4.5%). Clinically relevant adverse reactions in <10% of patients who received TALZENNA with enzalutamide included abdominal pain (9%), vomiting (9%), alopecia (7%), dyspepsia (4%), venous thromboembolism (3%) and stomatitis (2%). Based on animal studies, TALZENNA may impair fertility in males of reproductive potential. DRUG INTERACTIONS Coadministration with P-gp inhibitors The effect of coadministration of P-gp inhibitors on talazoparib exposure when TALZENNA is taken in combination with enzalutamide has not been studied. Monitor patients for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with a P-gp inhibitor. Coadministration with BCRP inhibitors Monitor patients for increased adverse reactions and modify the dosage as recommended for adverse reactions when TALZENNA is coadministered with a BCRP inhibitor. Coadministration of TALZENNA with BCRP inhibitors may increase talazoparib exposure, which may increase the risk of adverse reactions. USE IN SPECIFIC POPULATIONS Renal Impairment The recommended dosage of TALZENNA for patients with moderate renal impairment (CLcr 30 - 59 mL/min) is 0.35 mg taken orally once daily in combination with enzalutamide. The recommended dosage of TALZENNA for patients with severe renal impairment (CLcr 15 - 29 mL/min) is 0.25 mg taken orally once daily in combination with enzalutamide. No dose adjustment is required for patients with mild renal impairment. TALZENNA has not been studied in patients requiring hemodialysis. Please see full U.S. Prescribing Information and Patient Information for TALZENNA ® (talazoparib) at www.TALZENNA.com. About XTANDI ® (enzalutamide) and Important Safety Information XTANDI® (enzalutamide) is an androgen receptor signaling inhibitor. XTANDI is a standard of care and has received regulatory approvals in one or more countries around the world for use in men with metastatic castration-sensitive prostate cancer (mCSPC; also known as metastatic hormone-sensitive prostate cancer or mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). XTANDI is currently approved for one or more of these indications in more than 90 countries, including in the U.S., EU, and Japan. Over one million patients have been treated with XTANDI globally.6 What should I tell my doctor before taking XTANDI? Tell your doctor about all your medical conditions, including if you: Have a history of seizures, brain injury, stroke, or brain tumors. Have a history of heart disease, have high blood pressure, or have abnormal amounts of fat or cholesterol in your blood (dyslipidemia). Are pregnant or plan to become pregnant. XTANDI can cause harm to your unborn baby and loss of pregnancy (miscarriage). Have a partner who is pregnant or may become pregnant. Males who have female partners who are able to become pregnant should use effective birth control (contraception) during treatment with XTANDI and for 3 months after the last dose. Males must use a condom during sex with a pregnant female. Are breastfeeding or plan to breastfeed. It is not known if XTANDI passes into your breast milk. Take other medicines. XTANDI may affect the way other medicines work, and other medicines may affect how XTANDI works. These include prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not start or stop any medicine without talking to your doctor. How should I take XTANDI?Take XTANDI exactly as your doctor tells you. Take your prescribed dose once a day, at the same time each day. XTANDI can be taken with or without food. Swallow XTANDI capsules or tablets whole with enough water to make sure that you can swallow all of the medicine successfully. Do not chew, dissolve, or open the capsules. Do not cut, crush or chew the tablets. Your doctor may change your dose if needed. Your doctor may also change your pill size or stop treatment if you have swallowing problems. Do not change or stop taking your prescribed dose of XTANDI without talking with your doctor first. If you are receiving gonadotropin-releasing hormone (GnRH) therapy, you should continue with this treatment while taking XTANDI unless you have had surgery to lower the amount of testosterone in your body (surgical castration). If you miss a dose of XTANDI: Take your prescribed dose as soon as you remember that day. If you miss your daily dose, take your prescribed dose at your regular time the next day. Do not take more than your prescribed dose of XTANDI each day. If you take too much XTANDI: Call your doctor or go to the nearest emergency room right away. You may have an increased risk of seizure if you take too much XTANDI. What are the possible side effects of XTANDI? XTANDI may cause serious side effects including:Seizure. If you take XTANDI, you may be at risk of having a seizure. Avoid activities where a sudden loss of consciousness could seriously harm you or someone else. Tell your doctor right away if you lose consciousness or have a seizure. Posterior Reversible Encephalopathy Syndrome (PRES). If you take XTANDI you may be at risk of developing a condition involving the brain called PRES. Tell your doctor right away if you have a seizure or quickly worsening symptoms such as headache, decreased alertness, confusion, reduced eyesight, blurred vision or other visual problems. Your doctor will do a test to check for PRES. Allergic Reactions. Allergic reactions have happened in people who take XTANDI. Stop taking XTANDI and get medical help right away if you develop swelling of the face, tongue, lip or throat. Heart Disease. Blockage of the arteries in the heart (ischemic heart disease) that can lead to death has happened in some people during treatment with XTANDI. Your doctor will monitor you for signs and symptoms of heart problems during your treatment. Call your doctor or go to the emergency room right away if you get chest pain or discomfort at rest or with activity or shortness of breath during your treatment with XTANDI. Falls and Bone Fractures. XTANDI treatment may increase your risk for falls and bone fractures. Falls were not caused by loss of consciousness or seizures. Your doctor will monitor your risks for falls and bone fractures during treatment with XTANDI. Swallowing problems or choking. Severe swallowing problems or choking, including life-threatening problems or death can happen in people during treatment with XTANDI, because of the size of the XTANDI capsules and tablets. Swallow each XTANDI capsule or tablet whole with enough water to make sure that you can swallow all of the medicine successfully. Your doctor will stop treatment with XTANDI if you have serious side effects. The most common side effects of XTANDI include: Muscle and joint pain Feeling more tired than usual Hot flashes Constipation Decreased appetite Diarrhea High blood pressure Bleeding problems Falls Bone fractures Headache XTANDI may cause fertility problems in males, which may affect the ability to father children. Talk to your doctor if you have concerns about fertility. These are not all the possible side effects of XTANDI. For more information, talk to your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. About the Pfizer/Astellas Collaboration In October 2009, Medivation, Inc., which is now part of Pfizer (NYSE: PFE), and Astellas (TSE: 4503) entered into a global agreement to jointly develop and commercialize XTANDI ® (enzalutamide). The companies jointly commercialize XTANDI in the United States, and Astellas has responsibility for manufacturing and all additional regulatory filings globally, as well as commercializing XTANDI outside the United States. Disclosure Notice The information contained in this release is as of February 13, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer Oncology, TALZENNA and XTANDI, including their potential benefits, the TALAPRO-2 results, and potential updates of the approved labels for TALZENNA that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of TALZENNA in combination with XTANDI; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when applications for TALZENNA, XTANDI or a combination may be filed in any jurisdictions for any potential indications; whether and when any applications for TALZENNA, XTANDI or a combination that may be pending or filed may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether TALZENNA, XTANDI or a combination will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of TALZENNA, XTANDI or a combination; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. References Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians . 2024;74(3):229-263. Published 2024 April 4. doi: 10.3322/caac.21834 American Cancer Society. Key Statistics for Prostate Cancer. Accessed August 2024. *other than non-melanoma skin cancer Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011 Nov;65(11):1180-92. doi: 10.1111/j.1742-1241.2011.02799.x. PMID: 21995694. Shore N, Oliver L, Shui I, Gayle A, Wong OY, Kim J, Payne S, Amin S, Ghate S. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations. J Urol. 2021 Apr;205(4):977-986. doi: 10.1097/JU.0000000000001570. Epub 2020 Dec 17. PMID: 33332152. https://www.auajournals.org/doi/10.1097/JU.0000000000001570 National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Prostate Cancer, Bethesda, MD, USA (2022); USA. Accessed December 2024. https://seer.cancer.gov/statfacts/html/prost.html. Data on file. Northbrook, IL: Astellas Inc. View source version on businesswire.com: https://www.businesswire.com/news/home/20250213091824/en/

Are Investors Being Too Paranoid About Pfizer Stock?
Investing in a top healthcare company whose share price has been tanking in recent years could present a huge opportunity for investors, especially when that company has been bolstering its growth prospects via acquisitions and expansion of its pipeline. And if that stock trades at a cheap valuation and pays a high dividend, it would seem like a no-brainer buy today.

3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now
With thousands of publicly traded companies and exchange-traded funds (ETFs) to choose from, Wall Street offers no shortage of ways for investors to grow their wealth. But among this vast sea of pathways to become richer is one of the most-successful strategies: buying and holding high-quality dividend stocks.

U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grad.

Pfizer: 3 Key Risks That Warrant A Sell
Pfizer's business is facing material revenue shrink issues due to many patent expirations over the next 3 years. Quarterly revenue run rate analysis suggests management may be underestimating the impact. PFE continues to have recurring 'unusual charges.' Accounting for this, its EBIT margins are in barely profitable territory. The Company is trading at a 32% 1-yr fwd PE discount to peers, but I think this is deserved given its revenue and profitability challenges.

Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced additional follow-up results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) evaluating the efficacy and safety of PADCEV ® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA® (pembrolizumab), a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothel.

Pfizer: Challenges Loom Amid Overvaluation
I have downgraded Pfizer Inc. stock to Strong Sell due to stagnant revenue, substantial patent cliffs, regulatory, legal, and reputational headwinds, and overvaluation concerns. Despite a 24.7% YoY revenue growth in FQ4, Pfizer's financial flexibility remains weak with significant net debt and no new products to offset patent losses. Valuation analysis indicates PFE stock is overvalued with a fair share price below $25, and consensus estimates forecast a below 2% dividend growth rate for the next two fiscal years.

Better High-Yield Dividend Stock: Pfizer vs. Merck
Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (MRK -0.88%) that offer a yield above 3%, and shares of Pfizer (PFE -0.35%) offer a yield above 6%.

Fighting Cancer Becomes Top Priority for Pfizer
Pfizer chairman and CEO Albert Bourla sees cancer as Pfizer's next big chance to save the world. The complexity of cancers makes treatments expensive to develop and challenging to customize, but the approach of making life more livable with cancer is changing the face of the disease.

Income Strategy: I'm Stashing Cash Into These Wonderful Dividends
Inflation can be countered by investing in income-generating assets like consumer staples, energy, and pharmaceuticals, which provide essential products and reliable dividends. In this article, I highlight two such names that offer robust payouts which are well-covered by earnings. Both carry moat-worthy business models and have strong pipelines that support potential for robust total returns.

Should You Pick PFE Stock At $25?
Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 per share, compared to the consensus estimates of $17.4 billion and $0.46, respectively.

MoneyShow's Best Investment Ideas For 2025: Part 9
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with turnaround potential, along with some speculative plays and ETFs. Part 9 includes Ituran Location and Control, Lara Exploration, Imperial Oil, Avino Silver & Gold Mines, BBB Foods and Pfizer, among others.

Pfizer, Inc. (PFE) Q4 2024 Earnings Call Transcript
Pfizer, Inc. (NYSE:PFE ) Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ET Company Participants Francesca DeMartino - Senior Vice President, Chief Investor Relations Officer Albert Bourla - Chairman and Chief Executive Officer Dave Denton - Chief Financial Officer and Executive Vice President Chris Boshoff - Chief Scientific Officer and President of Research & Development Aamir Malik - Chief U.S. Commercial Officer and Executive Vice President Alexandre de Germay - Executive Vice President & Chief International Commercial Officer Andrew Baum - Chief Strategy & Innovation Officer and Executive Vice President Conference Call Participants Steve Scala - TD Cowen Geoff Meacham - Citibank Chris Schott - JPMorgan Vamil Divan - Guggenheim Securities Courtney Breen - Bernstein Evan Seigerman - BMO Capital Markets Kripa Devarakonda - Truist Securities Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Trung Huynh - UBS Akash Tewari - Jefferies Chris Shibutani - Goldman Sachs Alexandria Hammond - Wolfe Research Tim Anderson - Bank of America Operator Good day, everyone, and welcome to Pfizer's Fourth Quarter 2024 Earnings Conference Call. Today's call is being recorded.

Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job
Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vote by a Senate panel.

Pfizer's fourth quarter sales and earnings top expectations
Pfizer Inc (NYSE:PFE, ETR:PFE) posted stronger-than-expected financial results for the fourth quarter and reaffirmed its 2025 revenue guidance. The company continues to expect between $61 billion and $64 billion in revenue this year, with sales from Covid products expected to be stable year-over-year.

Pfizer Earnings
This section highlights Pfizer's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
---|---|---|---|---|---|
Read Transcript | Q4 | 2024 | 2025-02-04 | $0.47 | $0.63 |
Read Transcript | Q3 | 2024 | 2024-10-29 | $0.61 | $1.06 |
Read Transcript | Q2 | 2024 | 2024-07-30 | $0.46 | $0.60 |
Read Transcript | Q1 | 2024 | 2024-05-01 | $0.52 | $0.82 |
Read Transcript | Q4 | 2023 | 2024-01-30 | $-0.19 | $0.10 |
Read Transcript | Q3 | 2023 | 2023-10-31 | $-0.32 | $-0.17 |
Read Transcript | Q2 | 2023 | 2023-08-01 | $0.56 | $0.67 |
Read Transcript | Q1 | 2023 | 2023-05-02 | $0.98 | $1.23 |
Financial Statements
Access annual & quarterly financial statements for Pfizer, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|---|
Revenue | $63.63B | $58.50B | $100.33B | $81.29B | $41.91B |
Cost of Revenue | $17.85B | $29.69B | $34.34B | $30.82B | $8.69B |
Gross Profit | $45.78B | $28.81B | $65.99B | $50.47B | $33.22B |
Gross Profit Ratio | 71.94% | 49.25% | 65.77% | 62.08% | 79.26% |
Research and Development Expenses | $10.93B | $10.68B | $11.43B | $13.83B | $9.40B |
General and Administrative Expenses | $- | $11.07B | $10.88B | $10.70B | $9.81B |
Selling and Marketing Expenses | $- | $3.70B | $2.80B | $2.00B | $1.80B |
Selling General and Administrative Expenses | $14.73B | $14.77B | $13.68B | $12.70B | $11.62B |
Other Expenses | $5.18B | $- | $3.61B | $3.70B | $3.44B |
Operating Expenses | $30.84B | $25.45B | $28.71B | $30.23B | $24.46B |
Cost and Expenses | $42.12B | $55.14B | $63.06B | $61.05B | $33.15B |
Interest Income | $545.00M | $1.62B | $251.00M | $36.00M | $73.00M |
Interest Expense | $3.09B | $2.21B | $1.24B | $1.29B | $1.45B |
Depreciation and Amortization | $-3.82B | $6.29B | $5.06B | $5.19B | $4.68B |
EBITDA | $11.11B | $9.56B | $41.03B | $30.79B | $13.17B |
EBITDA Ratio | 17.47% | 16.34% | 43.50% | 35.10% | 33.56% |
Operating Income | $14.94B | $3.36B | $40.03B | $24.83B | $10.63B |
Operating Income Ratio | 23.48% | 5.74% | 39.90% | 30.55% | 25.37% |
Total Other Income Expenses Net | $-6.92B | $-2.30B | $-2.54B | $-2.67B | $-3.59B |
Income Before Tax | $8.02B | $1.06B | $34.73B | $24.31B | $7.50B |
Income Before Tax Ratio | 12.61% | 1.81% | 34.61% | 29.91% | 17.89% |
Income Tax Expense | $28.00M | $-1.11B | $3.33B | $1.85B | $477.00M |
Net Income | $8.03B | $2.12B | $31.37B | $21.98B | $7.02B |
Net Income Ratio | 12.62% | 3.62% | 31.27% | 27.04% | 16.75% |
EPS | $1.42 | $0.38 | $5.59 | $3.95 | $1.26 |
EPS Diluted | $1.41 | $0.37 | $5.47 | $3.88 | $1.25 |
Weighted Average Shares Outstanding | 5.66B | 5.64B | 5.61B | 5.60B | 5.55B |
Weighted Average Shares Outstanding Diluted | 5.70B | 5.71B | 5.73B | 5.71B | 5.63B |
SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
Breakdown | December 31, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | October 01, 2023 | July 02, 2023 | April 02, 2023 | December 31, 2022 | October 02, 2022 | July 03, 2022 | April 03, 2022 | December 31, 2021 | October 03, 2021 | July 04, 2021 | April 04, 2021 | December 31, 2020 | September 27, 2020 | June 28, 2020 | March 29, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $17.76B | $17.70B | $13.28B | $14.88B | $14.25B | $13.23B | $12.73B | $18.28B | $24.29B | $22.64B | $27.74B | $25.66B | $23.84B | $24.09B | $18.98B | $14.58B | $11.68B | $12.13B | $11.80B | $12.03B |
Cost of Revenue | $5.91B | $6.58B | $5.04B | $4.38B | $8.59B | $10.60B | $4.59B | $6.05B | $9.65B | $6.06B | $9.07B | $9.98B | $9.74B | $9.97B | $7.05B | $4.21B | $2.92B | $2.53B | $2.28B | $2.38B |
Gross Profit | $11.85B | $11.13B | $8.24B | $10.50B | $5.66B | $2.63B | $8.14B | $12.23B | $14.64B | $16.57B | $18.68B | $15.68B | $14.10B | $14.12B | $11.93B | $10.37B | $8.77B | $9.60B | $9.52B | $9.65B |
Gross Profit Ratio | 66.73% | 62.86% | 62.06% | 70.56% | 39.70% | 19.87% | 63.92% | 66.92% | 60.28% | 73.22% | 67.32% | 61.09% | 59.16% | 58.61% | 62.86% | 71.12% | 75.02% | 79.15% | 80.67% | 80.23% |
Research and Development Expenses | $3.12B | $2.60B | $2.68B | $2.48B | $2.77B | $2.68B | $2.63B | $2.49B | $3.62B | $2.70B | $2.81B | $2.30B | $5.92B | $3.45B | $2.46B | $2.01B | $3.35B | $2.36B | $2.13B | $1.72B |
General and Administrative Expenses | $- | $- | $- | $- | $777.00M | $- | $- | $- | $1.84B | $- | $- | $- | $2.10B | $- | $- | $- | $350.00M | $- | $-221.00M | $-129.00M |
Selling and Marketing Expenses | $- | $- | $- | $- | $3.70B | $- | $- | $- | $2.80B | $- | $- | $- | $2.00B | $- | $- | $- | $-5.90B | $- | $3.03B | $2.87B |
Selling General and Administrative Expenses | $4.27B | $3.24B | $3.69B | $3.46B | $4.48B | $3.21B | $3.43B | $3.36B | $4.64B | $3.39B | $2.91B | $2.59B | $4.10B | $2.90B | $2.93B | $2.78B | $3.76B | $3.02B | $3.03B | $2.87B |
Other Expenses | $1.27B | $- | $230.00M | $361.00M | $1.03B | $574.00M | $385.00M | $680.00M | $1.13B | $822.00M | $-104.00M | $835.00M | $1.31B | $1.48B | $650.00M | $658.00M | $641.00M | $122.00M | $274.00M | $318.00M |
Operating Expenses | $7.86B | $5.84B | $6.36B | $5.94B | $7.25B | $5.89B | $6.06B | $5.85B | $9.39B | $6.91B | $5.73B | $5.73B | $10.98B | $7.33B | $6.32B | $5.67B | $7.97B | $6.27B | $6.07B | $5.48B |
Cost and Expenses | $13.61B | $12.42B | $11.40B | $10.32B | $15.84B | $16.50B | $10.66B | $11.90B | $19.04B | $12.97B | $14.79B | $15.71B | $20.71B | $17.31B | $13.37B | $9.88B | $10.89B | $8.80B | $8.35B | $7.86B |
Interest Income | $170.00M | $116.00M | $130.00M | $129.00M | $609.00M | $523.00M | $316.00M | $177.00M | $137.00M | $70.00M | $30.00M | $14.00M | $14.00M | $10.00M | $13.00M | $- | $4.00M | $17.00M | $19.00M | $34.00M |
Interest Expense | $739.00M | $783.00M | $778.00M | $790.00M | $688.00M | $695.00M | $508.00M | $318.00M | $313.00M | $311.00M | $293.00M | $322.00M | $315.00M | $325.00M | $316.00M | $336.00M | $347.00M | $416.00M | $372.00M | $390.00M |
Depreciation and Amortization | $-2.46B | $1.75B | $1.73B | $1.74B | $1.67B | $1.56B | $1.57B | $1.49B | $1.52B | $1.18B | $1.18B | $1.19B | $1.28B | $1.36B | $1.68B | $1.21B | $1.05B | $1.21B | $1.20B | $1.17B |
EBITDA | $729.00M | $7.25B | $2.40B | $5.95B | $-1.77B | $-1.10B | $4.35B | $8.07B | $7.06B | $10.49B | $12.91B | $10.56B | $5.42B | $9.52B | $8.61B | $6.29B | $-1.20B | $4.47B | $4.59B | $4.40B |
EBITDA Ratio | 4.10% | 40.97% | 27.18% | 42.31% | 0.54% | -12.89% | 28.67% | 43.04% | 31.13% | 49.69% | 50.90% | 44.90% | 23.36% | 38.85% | 38.70% | 43.17% | 20.57% | 36.85% | 40.49% | 44.68% |
Operating Income | $3.19B | $5.28B | $1.88B | $4.56B | $-1.59B | $-3.27B | $2.08B | $6.38B | $6.43B | $10.43B | $12.95B | $10.69B | $4.04B | $6.47B | $5.31B | $4.70B | $-2.19B | $3.33B | $3.45B | $4.17B |
Operating Income Ratio | 17.94% | 29.85% | 14.15% | 30.64% | -11.18% | -24.68% | 16.32% | 34.91% | 26.48% | 46.06% | 46.67% | 41.64% | 16.96% | 26.87% | 27.97% | 32.25% | -18.74% | 27.43% | 29.26% | 34.65% |
Total Other Income Expenses Net | $-3.20B | $-569.00M | $-1.98B | $-1.14B | $-2.54B | $-404.00M | $-520.00M | $-303.00M | $-20.00M | $-665.00M | $-962.00M | $-898.00M | $-1.79B | $-991.00M | $785.00M | $521.00M | $4.11B | $647.00M | $500.00M | $475.00M |
Income Before Tax | $-10.00M | $4.71B | $-103.00M | $3.42B | $-4.13B | $-3.35B | $2.27B | $6.27B | $5.23B | $9.00B | $11.45B | $9.05B | $3.83B | $7.84B | $6.61B | $5.68B | $178.00M | $2.18B | $3.95B | $3.88B |
Income Before Tax Ratio | -0.06% | 26.64% | -0.78% | 22.99% | -28.98% | -25.33% | 17.82% | 34.30% | 21.54% | 39.76% | 41.26% | 35.27% | 16.05% | 32.52% | 34.83% | 38.97% | 1.52% | 17.94% | 33.50% | 32.30% |
Income Tax Expense | $-421.00M | $234.00M | $-134.00M | $293.00M | $-794.00M | $-964.00M | $-71.00M | $715.00M | $230.00M | $356.00M | $1.57B | $1.17B | $249.00M | $-331.00M | $1.04B | $805.00M | $-170.00M | $-26.00M | $519.00M | $475.00M |
Net Income | $410.00M | $4.46B | $24.00M | $3.12B | $-3.34B | $-2.39B | $2.33B | $5.54B | $4.99B | $8.61B | $9.91B | $7.86B | $3.39B | $8.15B | $5.56B | $4.88B | $594.00M | $2.19B | $3.49B | $3.35B |
Net Income Ratio | 2.31% | 25.22% | 0.18% | 20.94% | -23.47% | -18.09% | 18.27% | 30.32% | 20.56% | 38.02% | 35.71% | 30.65% | 14.23% | 33.81% | 29.31% | 33.45% | 5.08% | 18.09% | 29.57% | 27.89% |
EPS | $0.07 | $0.79 | $0.00 | $0.55 | $-0.59 | $-0.42 | $0.41 | $0.98 | $0.89 | $1.54 | $1.77 | $1.40 | $0.60 | $1.45 | $0.99 | $0.87 | $0.11 | $0.39 | $0.63 | $0.60 |
EPS Diluted | $0.07 | $0.78 | $0.00 | $0.55 | $-0.59 | $-0.42 | $0.41 | $0.97 | $0.87 | $1.51 | $1.73 | $1.37 | $0.59 | $1.42 | $0.98 | $0.86 | $0.10 | $0.39 | $0.62 | $0.60 |
Weighted Average Shares Outstanding | 5.67B | 5.67B | 5.67B | 5.66B | 5.65B | 5.65B | 5.65B | 5.63B | 5.62B | 5.61B | 5.59B | 5.62B | 5.62B | 5.61B | 5.60B | 5.58B | 5.56B | 5.56B | 5.55B | 5.54B |
Weighted Average Shares Outstanding Diluted | 5.70B | 5.71B | 5.70B | 5.70B | 5.65B | 5.65B | 5.71B | 5.73B | 5.74B | 5.72B | 5.71B | 5.76B | 5.77B | 5.72B | 5.68B | 5.66B | 5.66B | 5.63B | 5.62B | 5.61B |
SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|---|
Cash and Cash Equivalents | $- | $2.85B | $416.00M | $1.94B | $1.78B |
Short Term Investments | $- | $9.84B | $22.32B | $29.12B | $10.44B |
Cash and Short Term Investments | $9.95B | $12.69B | $22.73B | $31.07B | $12.22B |
Net Receivables | $- | $11.18B | $10.95B | $11.48B | $7.91B |
Inventory | $- | $10.19B | $8.98B | $9.06B | $8.05B |
Other Current Assets | $- | $9.28B | $8.59B | $8.09B | $6.91B |
Total Current Assets | $9.95B | $43.33B | $51.26B | $59.69B | $35.07B |
Property Plant Equipment Net | $- | $21.86B | $16.27B | $14.88B | $13.90B |
Goodwill | $- | $67.78B | $51.38B | $49.21B | $49.58B |
Intangible Assets | $- | $64.90B | $43.37B | $25.15B | $28.47B |
Goodwill and Intangible Assets | $- | $132.68B | $94.75B | $74.35B | $78.05B |
Long Term Investments | $- | $15.77B | $15.07B | $21.53B | $20.26B |
Tax Assets | $- | $3.71B | $6.69B | $3.34B | $2.38B |
Other Non-Current Assets | $-9.95B | $9.14B | $13.16B | $7.68B | $4.57B |
Total Non-Current Assets | $-9.95B | $183.17B | $145.94B | $121.78B | $119.16B |
Other Assets | $- | $- | $3.00M | $2.00M | $-1.00M |
Total Assets | $- | $226.50B | $197.21B | $181.48B | $154.23B |
Account Payables | $- | $6.71B | $6.81B | $5.58B | $4.28B |
Short Term Debt | $- | $10.35B | $-462.00M | $2.24B | $2.70B |
Tax Payables | $- | $2.35B | $1.59B | $1.27B | $1.05B |
Deferred Revenue | $- | $2.70B | $2.52B | $3.07B | $6.27B |
Other Current Liabilities | $- | $25.69B | $28.28B | $30.52B | $16.77B |
Total Current Liabilities | $- | $47.79B | $42.14B | $42.67B | $25.92B |
Long Term Debt | $- | $61.54B | $31.93B | $34.76B | $37.13B |
Deferred Revenue Non-Current | $- | $- | $- | $16.49B | $18.53B |
Deferred Tax Liabilities Non-Current | $- | $640.00M | $1.02B | $349.00M | $4.06B |
Other Non-Current Liabilities | $-92.56B | $27.24B | $26.20B | $26.24B | $23.64B |
Total Non-Current Liabilities | $-92.56B | $89.42B | $59.15B | $61.34B | $64.84B |
Other Liabilities | $- | $- | $- | $- | $- |
Total Liabilities | $-92.56B | $137.21B | $101.29B | $104.01B | $90.76B |
Preferred Stock | $- | $- | $- | $- | $- |
Common Stock | $- | $478.00M | $476.00M | $473.00M | $470.00M |
Retained Earnings | $- | $118.35B | $125.66B | $103.39B | $96.77B |
Accumulated Other Comprehensive Income Loss | $92.29B | $-7.96B | $-8.30B | $-5.90B | $-11.69B |
Other Total Stockholders Equity | $272.00M | $-21.86B | $-22.17B | $-20.77B | $-22.31B |
Total Stockholders Equity | $92.56B | $89.01B | $95.66B | $77.20B | $63.24B |
Total Equity | $92.56B | $89.29B | $95.92B | $77.46B | $63.47B |
Total Liabilities and Stockholders Equity | $- | $226.50B | $197.21B | $181.48B | $154.23B |
Minority Interest | $- | $274.00M | $256.00M | $262.00M | $235.00M |
Total Liabilities and Total Equity | $- | $226.50B | $197.21B | $181.48B | $154.23B |
Total Investments | $- | $25.20B | $37.38B | $50.65B | $30.70B |
Total Debt | $- | $70.84B | $34.87B | $37.00B | $38.27B |
Net Debt | $- | $67.99B | $34.45B | $35.05B | $36.49B |
Balance Sheet Charts
Breakdown | December 31, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | October 01, 2023 | July 02, 2023 | April 02, 2023 | December 31, 2022 | October 02, 2022 | July 03, 2022 | April 03, 2022 | December 31, 2021 | October 03, 2021 | July 04, 2021 | April 04, 2021 | December 31, 2020 | September 27, 2020 | June 28, 2020 | March 29, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and Cash Equivalents | $- | $1.09B | $1.05B | $719.00M | $2.85B | $3.15B | $2.63B | $2.17B | $416.00M | $1.30B | $1.78B | $2.47B | $1.94B | $1.97B | $2.37B | $1.77B | $1.78B | $1.59B | $1.80B | $2.15B |
Short Term Investments | $- | $8.86B | $6.05B | $11.21B | $9.84B | $41.03B | $42.15B | $17.81B | $22.32B | $34.83B | $31.52B | $21.43B | $29.12B | $27.73B | $19.33B | $11.90B | $10.44B | $8.91B | $9.58B | $8.20B |
Cash and Short Term Investments | $9.95B | $9.95B | $7.10B | $11.93B | $12.69B | $44.18B | $44.78B | $19.97B | $22.73B | $36.12B | $33.30B | $23.90B | $31.07B | $29.70B | $21.70B | $13.67B | $12.22B | $10.50B | $11.38B | $10.35B |
Net Receivables | $- | $14.45B | $11.39B | $10.99B | $11.18B | $11.09B | $10.23B | $12.30B | $10.95B | $16.08B | $15.15B | $13.22B | $11.48B | $11.90B | $10.59B | $9.86B | $7.93B | $10.01B | $9.13B | $9.88B |
Inventory | $- | $11.72B | $11.45B | $10.89B | $10.19B | $10.20B | $10.31B | $9.54B | $8.98B | $9.51B | $10.45B | $9.98B | $9.06B | $8.64B | $8.95B | $8.49B | $8.05B | $9.29B | $8.56B | $8.42B |
Other Current Assets | $- | $7.10B | $7.88B | $8.61B | $9.28B | $8.54B | $8.02B | $8.26B | $8.59B | $8.69B | $8.55B | $7.32B | $8.09B | $7.67B | $7.58B | $7.51B | $6.87B | $17.93B | $17.35B | $6.08B |
Total Current Assets | $9.95B | $43.22B | $37.83B | $42.41B | $43.33B | $74.01B | $73.35B | $50.08B | $51.26B | $70.40B | $67.47B | $54.42B | $59.69B | $57.90B | $48.81B | $39.53B | $35.07B | $47.74B | $46.42B | $34.74B |
Property Plant Equipment Net | $- | $18.54B | $18.96B | $18.80B | $21.86B | $17.86B | $17.49B | $17.05B | $16.27B | $15.44B | $15.24B | $15.11B | $14.88B | $14.44B | $14.22B | $14.01B | $13.90B | $14.40B | $14.11B | $14.04B |
Goodwill | $- | $68.57B | $68.44B | $69.30B | $67.78B | $51.53B | $51.57B | $51.48B | $51.38B | $49.44B | $49.89B | $50.21B | $49.21B | $49.49B | $49.87B | $49.79B | $49.58B | $59.90B | $58.45B | $58.50B |
Intangible Assets | $- | $59.99B | $61.24B | $62.83B | $64.90B | $40.22B | $41.41B | $42.00B | $43.37B | $28.15B | $29.07B | $29.82B | $25.15B | $26.31B | $27.32B | $27.97B | $28.47B | $30.93B | $33.54B | $34.46B |
Goodwill and Intangible Assets | $- | $128.56B | $129.69B | $132.12B | $132.68B | $91.75B | $92.98B | $93.48B | $94.75B | $77.59B | $78.96B | $80.03B | $74.35B | $75.80B | $77.19B | $77.76B | $78.05B | $90.83B | $91.99B | $92.97B |
Long Term Investments | $- | $10.76B | $11.52B | $12.00B | $15.77B | $14.65B | $15.36B | $15.04B | $15.07B | $13.89B | $19.52B | $20.74B | $21.53B | $21.60B | $20.94B | $20.23B | $20.26B | $19.01B | $18.72B | $18.22B |
Tax Assets | $- | $7.91B | $7.87B | $4.94B | $3.71B | $8.35B | $8.26B | $7.30B | $6.69B | $7.14B | $7.00B | $5.67B | $3.34B | $2.75B | $2.69B | $2.54B | $2.38B | $2.65B | $2.36B | $2.21B |
Other Non-Current Assets | $-9.95B | $10.48B | $10.34B | $10.81B | $9.14B | $8.39B | $12.73B | $12.67B | $13.16B | $10.89B | $7.10B | $7.88B | $7.68B | $6.71B | $6.06B | $4.74B | $4.57B | $4.36B | $4.33B | $4.17B |
Total Non-Current Assets | $-9.95B | $176.25B | $178.37B | $178.68B | $183.17B | $141.01B | $146.82B | $145.54B | $145.94B | $124.95B | $127.82B | $129.42B | $121.78B | $121.29B | $121.11B | $119.28B | $119.16B | $131.25B | $131.51B | $131.60B |
Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $3.00M | $- | $- | $1.00M | $2.00M | $- | $- | $1.00M | $-1.00M | $-1.00M | $-1.00M | $-1.00M |
Total Assets | $- | $219.48B | $216.19B | $221.09B | $226.50B | $215.02B | $220.17B | $195.62B | $197.21B | $195.35B | $195.29B | $183.84B | $181.48B | $179.19B | $169.92B | $158.82B | $154.23B | $178.98B | $177.93B | $166.34B |
Account Payables | $- | $5.31B | $5.11B | $5.59B | $6.71B | $5.34B | $6.08B | $6.12B | $6.81B | $6.27B | $6.21B | $5.51B | $5.58B | $4.70B | $4.33B | $4.06B | $4.31B | $4.14B | $3.87B | $3.97B |
Short Term Debt | $- | $9.70B | $9.38B | $8.23B | $7.57B | $2.55B | $2.01B | $4.19B | $-462.00M | $4.04B | $5.99B | $645.00M | $2.24B | $1.06B | $1.87B | $4.35B | $2.70B | $13.36B | $13.08B | $16.01B |
Tax Payables | $- | $2.88B | $2.88B | $3.19B | $2.35B | $1.90B | $2.93B | $1.97B | $1.59B | $3.07B | $3.35B | $3.18B | $1.27B | $4.50B | $1.74B | $1.40B | $1.05B | $1.43B | $1.45B | $1.15B |
Deferred Revenue | $- | $2.02B | $2.53B | $2.50B | $2.70B | $2.20B | $1.29B | $1.75B | $2.52B | $6.19B | $3.80B | $3.11B | $3.07B | $3.53B | $4.29B | $2.05B | $6.27B | $5.97B | $5.60B | $3.40B |
Other Current Liabilities | $- | $23.30B | $21.36B | $20.98B | $25.68B | $19.15B | $20.37B | $22.53B | $28.28B | $24.75B | $28.06B | $26.83B | $30.52B | $25.45B | $21.42B | $14.78B | $17.86B | $15.22B | $14.32B | $12.76B |
Total Current Liabilities | $- | $43.21B | $43.82B | $40.50B | $47.79B | $31.14B | $34.65B | $36.56B | $42.14B | $44.31B | $47.41B | $39.27B | $42.67B | $41.80B | $35.66B | $26.65B | $25.92B | $34.15B | $32.72B | $33.89B |
Long Term Debt | $- | $58.00B | $57.51B | $61.31B | $61.54B | $61.05B | $61.36B | $31.70B | $31.93B | $31.65B | $34.29B | $34.42B | $34.76B | $36.25B | $35.35B | $35.35B | $37.13B | $49.78B | $50.53B | $36.28B |
Deferred Revenue Non-Current | $- | $- | $- | $- | $2.63B | $- | $- | $- | $- | $- | $- | $- | $16.49B | $17.11B | $17.70B | $18.43B | $18.53B | $19.78B | $17.90B | $18.75B |
Deferred Tax Liabilities Non-Current | $- | $2.16B | $2.23B | $931.00M | $640.00M | $1.12B | $1.23B | $1.07B | $1.02B | $616.00M | $558.00M | $655.00M | $349.00M | $328.00M | $4.16B | $4.36B | $4.06B | $4.54B | $5.41B | $5.27B |
Other Non-Current Liabilities | $-92.56B | $23.55B | $24.67B | $25.80B | $27.24B | $24.51B | $23.64B | $25.05B | $26.20B | $25.88B | $25.56B | $26.82B | $26.24B | $24.84B | $24.43B | $23.60B | $23.64B | $25.01B | $24.71B | $25.56B |
Total Non-Current Liabilities | $-92.56B | $83.71B | $84.40B | $88.04B | $89.42B | $86.68B | $86.23B | $57.82B | $59.15B | $58.15B | $60.41B | $61.89B | $61.34B | $61.42B | $63.94B | $63.30B | $64.84B | $79.33B | $80.65B | $67.11B |
Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
Total Liabilities | $-92.56B | $126.92B | $128.22B | $128.54B | $137.21B | $117.82B | $120.87B | $94.38B | $101.29B | $102.46B | $107.82B | $101.16B | $104.01B | $103.22B | $99.61B | $89.95B | $90.76B | $113.49B | $113.37B | $101.00B |
Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $17.00M |
Common Stock | $- | $480.00M | $480.00M | $480.00M | $478.00M | $478.00M | $478.00M | $478.00M | $476.00M | $476.00M | $476.00M | $476.00M | $473.00M | $473.00M | $472.00M | $472.00M | $470.00M | $470.00M | $470.00M | $470.00M |
Retained Earnings | $- | $121.06B | $116.60B | $121.32B | $118.35B | $126.41B | $128.80B | $131.10B | $125.66B | $122.97B | $116.61B | $111.19B | $103.39B | $102.25B | $96.35B | $95.16B | $96.77B | $100.28B | $100.20B | $101.00B |
Accumulated Other Comprehensive Income Loss | $92.29B | $-7.97B | $-7.82B | $-7.76B | $-7.96B | $-7.97B | $-8.10B | $-8.29B | $-8.30B | $-8.22B | $-7.12B | $-6.16B | $-5.90B | $-5.65B | $-4.76B | $-4.66B | $-11.69B | $-12.68B | $-13.25B | $-13.13B |
Other Total Stockholders Equity | $272.00M | $-21.28B | $-21.56B | $-21.76B | $-21.86B | $-21.99B | $-22.15B | $-22.32B | $-22.17B | $-22.59B | $-22.76B | $-23.09B | $-20.77B | $-21.39B | $-22.02B | $-22.35B | $-22.31B | $-22.82B | $-23.09B | $-23.33B |
Total Stockholders Equity | $92.56B | $92.29B | $87.70B | $92.28B | $89.01B | $96.93B | $99.02B | $100.97B | $95.66B | $92.63B | $87.21B | $82.42B | $77.20B | $75.69B | $70.04B | $68.62B | $63.24B | $65.26B | $64.34B | $65.03B |
Total Equity | $92.56B | $92.56B | $87.97B | $92.56B | $89.29B | $97.20B | $99.29B | $101.24B | $95.92B | $92.89B | $87.47B | $82.69B | $77.46B | $75.97B | $70.31B | $68.86B | $63.47B | $65.50B | $64.56B | $65.34B |
Total Liabilities and Stockholders Equity | $- | $219.48B | $216.19B | $221.09B | $226.50B | $215.02B | $220.17B | $195.62B | $197.21B | $195.35B | $195.29B | $183.84B | $181.48B | $179.19B | $169.92B | $158.82B | $154.23B | $178.98B | $177.93B | $166.34B |
Minority Interest | $- | $272.00M | $275.00M | $276.00M | $274.00M | $270.00M | $274.00M | $266.00M | $256.00M | $259.00M | $261.00M | $261.00M | $262.00M | $275.00M | $273.00M | $245.00M | $235.00M | $236.00M | $228.00M | $312.00M |
Total Liabilities and Total Equity | $- | $219.48B | $216.19B | $221.09B | $226.50B | $215.02B | $220.17B | $195.62B | $197.21B | $195.35B | $195.29B | $183.84B | $181.48B | $179.19B | $169.92B | $158.82B | $154.23B | $178.98B | $177.93B | $166.34B |
Total Investments | $- | $19.62B | $17.57B | $23.21B | $25.61B | $55.69B | $57.51B | $32.84B | $37.38B | $48.71B | $51.05B | $42.16B | $50.65B | $49.33B | $40.27B | $32.13B | $30.70B | $27.92B | $28.30B | $26.42B |
Total Debt | $- | $66.62B | $69.45B | $69.54B | $75.04B | $63.60B | $65.34B | $35.89B | $34.87B | $35.68B | $40.28B | $35.05B | $37.00B | $38.41B | $37.73B | $38.19B | $38.27B | $61.53B | $63.61B | $52.28B |
Net Debt | $- | $65.53B | $68.40B | $68.82B | $72.19B | $60.45B | $62.71B | $33.73B | $34.45B | $34.38B | $38.50B | $32.58B | $35.05B | $36.44B | $35.36B | $36.42B | $36.49B | $59.94B | $61.81B | $50.13B |
Annual Cash Flow
Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
---|---|---|---|---|---|
Net Income | $8.03B | $2.17B | $31.40B | $22.46B | $7.02B |
Depreciation and Amortization | $- | $6.29B | $5.06B | $5.19B | $4.78B |
Deferred Income Tax | $- | $-3.44B | $-3.76B | $-4.29B | $-1.47B |
Stock Based Compensation | $- | $525.00M | $872.00M | $1.18B | $756.00M |
Change in Working Capital | $- | $-2.17B | $-4.46B | $12.80B | $-275.00M |
Accounts Receivables | $- | $347.00M | $261.00M | $-3.81B | $-1.25B |
Inventory | $- | $6.20B | $592.00M | $-1.12B | $-736.00M |
Accounts Payables | $- | $-300.00M | $1.19B | $1.24B | $353.00M |
Other Working Capital | $- | $-8.42B | $-6.50B | $16.50B | $1.36B |
Other Non Cash Items | $-8.03B | $5.33B | $150.00M | $-4.76B | $3.59B |
Net Cash Provided by Operating Activities | $- | $8.70B | $29.27B | $32.58B | $14.40B |
Investments in Property Plant and Equipment | $- | $-3.91B | $-3.24B | $-2.71B | $-2.79B |
Acquisitions Net | $- | $-43.43B | $-23.00B | $-12.00M | $-621.00M |
Purchases of Investments | $- | $-31.18B | $-38.78B | $-47.61B | $-14.40B |
Sales Maturities of Investments | $- | $46.42B | $45.46B | $28.10B | $12.73B |
Other Investing Activities | $- | $-180.00M | $3.77B | $-306.00M | $813.00M |
Net Cash Used for Investing Activities | $- | $-32.28B | $-15.78B | $-22.55B | $-4.27B |
Debt Repayment | $- | $35.95B | $-3.52B | $-1.10B | $-12.76B |
Common Stock Issued | $- | $- | $- | $- | $- |
Common Stock Repurchased | $- | $- | $-2.00B | $- | $- |
Dividends Paid | $- | $-9.25B | $-8.98B | $-8.73B | $-8.44B |
Other Financing Activities | $- | $-632.00M | $-335.00M | $16.00M | $11.55B |
Net Cash Used Provided by Financing Activities | $- | $26.07B | $-14.83B | $-9.82B | $-9.65B |
Effect of Forex Changes on Cash | $- | $-40.00M | $-165.00M | $-59.00M | $-8.00M |
Net Change in Cash | $-2.92B | $2.45B | $-1.51B | $158.00M | $475.00M |
Cash at End of Period | $- | $2.92B | $468.00M | $1.98B | $1.82B |
Cash at Beginning of Period | $2.92B | $468.00M | $1.98B | $1.82B | $1.35B |
Operating Cash Flow | $- | $8.70B | $29.27B | $32.58B | $14.40B |
Capital Expenditure | $- | $-3.91B | $-3.24B | $-2.71B | $-2.79B |
Free Cash Flow | $- | $4.79B | $26.03B | $29.87B | $11.61B |
Cash Flow Charts
Breakdown | December 31, 2024 | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | October 01, 2023 | July 02, 2023 | April 02, 2023 | December 31, 2022 | October 02, 2022 | July 03, 2022 | April 03, 2022 | December 31, 2021 | October 03, 2021 | July 04, 2021 | April 04, 2021 | December 31, 2020 | September 27, 2020 | June 28, 2020 | March 29, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | $410.00M | $4.47B | $24.00M | $3.12B | $-3.34B | $-2.39B | $2.33B | $5.54B | $5.00B | $8.64B | $9.87B | $7.88B | $3.85B | $8.17B | $5.57B | $4.88B | $-2.02B | $2.20B | $3.44B | $3.41B |
Depreciation and Amortization | $- | $1.75B | $1.73B | $1.74B | $1.67B | $1.56B | $1.57B | $1.49B | $1.52B | $1.18B | $1.18B | $1.19B | $1.28B | $1.36B | $1.33B | $1.23B | $1.05B | $1.26B | $1.25B | $1.22B |
Deferred Income Tax | $- | $-482.00M | $-783.00M | $-441.00M | $-1.86B | $-113.00M | $-873.00M | $-598.00M | $-365.00M | $62.00M | $-1.14B | $-2.32B | $-591.00M | $-3.75B | $-152.00M | $199.00M | $-871.00M | $-668.00M | $-38.00M | $109.00M |
Stock Based Compensation | $- | $274.00M | $206.00M | $220.00M | $121.00M | $151.00M | $148.00M | $105.00M | $364.00M | $135.00M | $287.00M | $86.00M | $495.00M | $293.00M | $221.00M | $172.00M | $264.00M | $224.00M | $187.00M | $57.00M |
Change in Working Capital | $- | $6.87B | $-3.54B | $-3.34B | $8.45B | $-1.20B | $-3.92B | $-5.51B | $3.15B | $-4.11B | $-2.77B | $-730.00M | $1.99B | $6.42B | $5.72B | $-1.33B | $2.81B | $-851.00M | $-648.00M | $-1.58B |
Accounts Receivables | $- | $- | $- | $- | $347.00M | $- | $- | $- | $261.00M | $- | $- | $- | $-3.81B | $- | $- | $- | $-1.25B | $- | $- | $- |
Inventory | $- | $- | $- | $- | $-1.17B | $- | $- | $- | $592.00M | $- | $- | $- | $-1.12B | $- | $- | $- | $-736.00M | $- | $- | $- |
Accounts Payables | $- | $- | $- | $- | $822.00M | $- | $- | $- | $1.19B | $- | $- | $- | $1.24B | $- | $- | $- | $353.00M | $- | $- | $- |
Other Working Capital | $- | $6.87B | $-3.54B | $-3.34B | $8.45B | $-1.20B | $-3.92B | $-5.51B | $1.10B | $-4.11B | $-2.77B | $-730.00M | $5.68B | $6.76B | $5.38B | $-1.33B | $4.44B | $-851.00M | $-648.00M | $-1.58B |
Other Non Cash Items | $-410.00M | $-6.18B | $4.24B | $3.48B | $201.00M | $5.45B | $-470.00M | $184.00M | $-1.09B | $59.00M | $3.38B | $440.00M | $-1.10B | $-1.66B | $-1.39B | $-609.00M | $4.41B | $-88.00M | $-639.00M | $-87.00M |
Net Cash Provided by Operating Activities | $- | $6.71B | $-1.78B | $1.09B | $5.24B | $3.46B | $-1.21B | $1.21B | $8.58B | $5.97B | $8.17B | $6.54B | $5.91B | $10.83B | $11.30B | $4.54B | $5.62B | $2.09B | $3.56B | $3.13B |
Investments in Property Plant and Equipment | $- | $-651.00M | $-637.00M | $-704.00M | $-1.04B | $-810.00M | $-914.00M | $-1.14B | $-1.00B | $-841.00M | $-751.00M | $-643.00M | $-993.00M | $-624.00M | $-540.00M | $-554.00M | $-1.29B | $-530.00M | $-480.00M | $-495.00M |
Acquisitions Net | $- | $- | $- | $3.49B | $-43.41B | $-2.00M | $-25.00M | $-1.00M | $-16.77B | $- | $- | $-6.22B | $-12.00M | $- | $- | $- | $-583.00M | $-5.00M | $-1.00M | $-32.00M |
Purchases of Investments | $- | $-2.67B | $657.00M | $-2.02B | $-874.00M | $-9.21B | $-14.38B | $-6.72B | $3.42B | $-18.79B | $-17.39B | $-9.43B | $-13.32B | $-17.71B | $-9.51B | $-7.08B | $5.93B | $-3.08B | $-14.27B | $-2.99B |
Sales Maturities of Investments | $- | $1.26B | $4.60B | $4.45B | $34.31B | $10.56B | $-9.64B | $11.19B | $9.93B | $15.16B | $6.90B | $16.88B | $11.68B | $8.55B | $2.15B | $5.72B | $3.69B | $3.91B | $1.72B | $3.41B |
Other Investing Activities | $- | $6.00M | $-18.00M | $1.00M | $15.00M | $350.00M | $-524.00M | $-18.00M | $9.00M | $3.85B | $-77.00M | $-13.00M | $64.00M | $-298.00M | $-235.00M | $163.00M | $582.00M | $178.00M | $17.00M | $36.00M |
Net Cash Used for Investing Activities | $- | $-2.06B | $4.60B | $1.73B | $-11.00B | $888.00M | $-25.48B | $3.31B | $-4.41B | $-627.00M | $-11.31B | $567.00M | $-2.59B | $-10.08B | $-8.14B | $-1.75B | $8.33B | $481.00M | $-13.01B | $-71.00M |
Debt Repayment | $- | $-2.25B | $-16.00M | $-2.17B | $7.78B | $-1.43B | $29.63B | $-32.00M | $-2.78B | $-3.52B | $4.61B | $-1.83B | $-1.36B | $759.00M | $-474.00M | $-25.00M | $-23.48B | $-647.00M | $11.32B | $18.00M |
Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $425.00M | $- | $- | $- |
Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $2.00K | $- | $- | $-2.00B | $- | $- | $- | $- | $-1.32B | $- | $- | $- |
Dividends Paid | $- | $-2.38B | $-2.38B | $-2.37B | $-2.31B | $-2.31B | $-2.31B | $-2.30B | $-2.25B | $-2.25B | $-2.24B | $-2.25B | $-2.19B | $-2.19B | $-2.18B | $-2.17B | $-2.11B | $-2.11B | $-2.11B | $-2.10B |
Other Financing Activities | $- | $-6.00M | $-63.00M | $-386.00M | $-18.00M | $-37.00M | $-141.00M | $-436.00M | $7.00M | $5.00M | $153.00M | $-500.00M | $201.00M | $325.00M | $100.00M | $-610.00M | $11.80B | $-62.00M | $-50.00M | $-113.00M |
Net Cash Used Provided by Financing Activities | $- | $-4.64B | $-2.46B | $-4.93B | $5.44B | $-3.78B | $27.17B | $-2.77B | $-5.01B | $-5.76B | $2.52B | $-6.58B | $-3.35B | $-1.10B | $-2.56B | $-2.81B | $-13.79B | $-2.82B | $9.16B | $-2.20B |
Effect of Forex Changes on Cash | $- | $9.00M | $-18.00M | $-28.00M | $-1.00M | $-32.00M | $-5.00M | $-2.00M | $-26.00M | $-72.00M | $-66.00M | $-1.00M | $-27.00M | $-37.00M | $5.00M | $- | $31.00M | $31.00M | $-55.00M | $-15.00M |
Net Change in Cash | $-1.15B | $100.00M | $333.00M | $-2.13B | $-295.00M | $516.00M | $466.00M | $1.75B | $-870.00M | $-486.00M | $-690.00M | $530.00M | $-51.00M | $-384.00M | $609.00M | $-16.00M | $198.00M | $-218.00M | $-351.00M | $846.00M |
Cash at End of Period | $- | $1.15B | $1.05B | $719.00M | $2.85B | $3.15B | $2.63B | $2.17B | $468.00M | $1.34B | $1.78B | $2.51B | $1.98B | $2.03B | $2.42B | $1.81B | $1.82B | $1.63B | $1.84B | $2.20B |
Cash at Beginning of Period | $1.15B | $1.05B | $719.00M | $2.85B | $3.15B | $2.63B | $2.17B | $416.00M | $1.34B | $1.82B | $2.47B | $1.98B | $2.03B | $2.42B | $1.81B | $1.82B | $1.63B | $1.84B | $2.20B | $1.35B |
Operating Cash Flow | $- | $6.71B | $-1.78B | $1.09B | $5.24B | $3.46B | $-1.21B | $1.21B | $8.58B | $5.97B | $8.17B | $6.54B | $5.91B | $10.83B | $11.30B | $4.54B | $5.62B | $2.09B | $3.56B | $3.13B |
Capital Expenditure | $- | $-651.00M | $-637.00M | $-704.00M | $-1.04B | $-810.00M | $-914.00M | $-1.14B | $-1.00B | $-841.00M | $-751.00M | $-643.00M | $-993.00M | $-624.00M | $-540.00M | $-554.00M | $-1.29B | $-530.00M | $-480.00M | $-495.00M |
Free Cash Flow | $- | $6.06B | $-2.42B | $387.00M | $4.20B | $2.65B | $-2.12B | $74.00M | $7.58B | $5.13B | $7.42B | $5.90B | $4.92B | $10.21B | $10.76B | $3.98B | $4.34B | $1.56B | $3.08B | $2.64B |
Pfizer Stock Forecast
Analyst ratings, price targets, and earnings estimates for PFE.
PFE Analyst Ratings
Hold
Based on 21 analysts in the past 3 months
PFE Stock 12 Month Forecast
$32.00
Based on 1 analysts in the last 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
Date | Analyst | Firm | Price Target | Price When Posted | Upside |
---|---|---|---|---|---|
Dec 18, 2024 | Robyn Karnauskas | Truist Financial | $32.00 | $25.89 | 23.6% |
Oct 30, 2024 | Chris Shibutani | Goldman Sachs | $33.00 | $28.46 | 16.0% |
Oct 17, 2024 | Courtney Breen | Bernstein | $32.00 | $29.67 | 7.9% |
Sep 25, 2024 | Carter Gould | Barclays | $32.00 | $28.93 | 10.6% |
Aug 07, 2024 | Narumi Nakagiri | Daiwa | $34.00 | $28.85 | 17.9% |
Jul 31, 2024 | Mohit Bansal | Wells Fargo | $30.00 | $31.39 | -4.4% |
Jul 31, 2024 | Chris Shibutani | Goldman Sachs | $34.00 | $31.39 | 8.3% |
Jul 30, 2024 | Vamil Divan | Guggenheim | $36.00 | $30.72 | 17.2% |
Jul 10, 2024 | Carter Gould | Barclays | $30.00 | $27.72 | 8.2% |
May 22, 2024 | Evan Seigerman | BMO Capital | $36.00 | $29.60 | 21.6% |
Pfizer Dividends
Explore Pfizer's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
0.00x
Pfizer Dividend History
Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
---|---|---|---|---|---|
$0.43 | $0.43 | January 24, 2025 | January 24, 2025 | March 07, 2025 | December 12, 2024 |
$0.42 | $0.42 | November 08, 2024 | November 08, 2024 | December 02, 2024 | October 09, 2024 |
$0.42 | $0.42 | July 26, 2024 | July 26, 2024 | September 03, 2024 | June 26, 2024 |
$0.42 | $0.42 | May 09, 2024 | May 10, 2024 | June 14, 2024 | April 24, 2024 |
$0.42 | $0.42 | January 25, 2024 | January 26, 2024 | March 01, 2024 | December 14, 2023 |
$0.41 | $0.41 | November 09, 2023 | November 10, 2023 | December 04, 2023 | October 04, 2023 |
$0.41 | $0.41 | July 27, 2023 | July 28, 2023 | September 05, 2023 | June 22, 2023 |
$0.41 | $0.41 | May 11, 2023 | May 12, 2023 | June 09, 2023 | April 26, 2023 |
$0.41 | $0.41 | January 26, 2023 | January 27, 2023 | March 03, 2023 | December 09, 2022 |
$0.4 | $0.4 | November 03, 2022 | November 04, 2022 | December 05, 2022 | September 22, 2022 |
$0.4 | $0.4 | July 28, 2022 | July 29, 2022 | September 06, 2022 | June 23, 2022 |
$0.4 | $0.4 | May 12, 2022 | May 13, 2022 | June 10, 2022 | April 28, 2022 |
$0.4 | $0.4 | January 27, 2022 | January 28, 2022 | March 04, 2022 | December 10, 2021 |
$0.39 | $0.39 | November 04, 2021 | November 05, 2021 | December 06, 2021 | September 23, 2021 |
$0.39 | $0.39 | July 29, 2021 | July 30, 2021 | September 07, 2021 | June 24, 2021 |
$0.39 | $0.39 | May 06, 2021 | May 07, 2021 | June 04, 2021 | April 22, 2021 |
$0.39 | $0.39 | January 28, 2021 | January 29, 2021 | March 05, 2021 | December 11, 2020 |
$0.38 | $0.38 | November 05, 2020 | November 06, 2020 | December 01, 2020 | September 24, 2020 |
$0.38 | $0.38 | July 30, 2020 | July 31, 2020 | September 01, 2020 | June 25, 2020 |
$0.38 | $0.38 | May 07, 2020 | May 08, 2020 | June 05, 2020 | April 23, 2020 |
Peers: Drug Manufacturers - General
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
---|---|---|---|---|---|
![]() AbbVie Inc.
ABBV
|
$340.83B | $192.87 | $2.75 | $56.34 | $26.45 |
![]() Merck & Co., Inc.
MRK
|
$209.99B | $83.01 | $0.14 | $778.71 | $7.56 |
![]() Eli Lilly and Company
LLY
|
$801.48B | $844.27 | $11.71 | $65.93 | $48.75 |
![]() Bristol-Myers Squibb Company
BMY
|
$109.32B | $53.90 | $-4.41 | $-12.82 | $7.02 |
![]() Johnson & Johnson
JNJ
|
$375.95B | $156.15 | $5.84 | $24.53 | $27385.90 |
![]() Amgen Inc.
AMGN
|
$156.51B | $291.16 | $7.56 | $34.48 | $23.99 |
![]() Gilead Sciences, Inc.
GILD
|
$129.71B | $104.08 | $0.38 | $239.97 | $0.00 |
Related Metrics
Explore detailed financial metrics and analysis for PFE.